SIMILAR PATTERNS OF AMINO ACIDS FOR 5J5X_B_AZ1B2

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1gng	GLYCOGEN SYNTHASE KINASE-3 BETA (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 63 GLY A 65 SER A 66 VAL A 70 LYS A 85 ASP A 200	None	0.56A	5j5xA-1gngA: 25.1	5j5xA-1gngA: 23.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1gzk	RAC-BETA SERINE/THREONINE PROTEIN KINASE (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	4	GLY A 159 GLY A 161 VAL A 166 LYS A 181	None	0.37A	5j5xA-1gzkA: 31.0	5j5xA-1gzkA: 39.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	5	GLY A 202 GLY A 204 VAL A 209 LYS A 222 ASP A 332	None	0.76A	5j5xA-1k9aA: 24.3	5j5xA-1k9aA: 21.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1kob	TWITCHIN (Aplysia californica)	PF00069 (Pkinase)	4	GLY A 60 GLY A 62 VAL A 67 LYS A 82	None	0.40A	5j5xA-1kobA: 24.6	5j5xA-1kobA: 26.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1m2p	CASEIN KINASE II, ALPHA CHAIN (Zea mays)	PF00069 (Pkinase)	4	GLY A 46 GLY A 48 VAL A 53 LYS A 68	HNA A 351 (-2.8A) HNA A 351 ( 4.6A) HNA A 351 (-4.5A) HNA A 351 (-2.6A)	0.43A	5j5xA-1m2pA: 24.5	5j5xA-1m2pA: 23.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1nxk	MAP KINASE-ACTIVATED PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	4	GLY A 71 VAL A 78 LYS A 93 ASP A 207	STU A 401 (-3.6A) STU A 401 (-4.7A) STU A 401 ( 4.5A) STU A 401 (-3.6A)	0.42A	5j5xA-1nxkA: 21.9	5j5xA-1nxkA: 28.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1tki	TITIN (Homo sapiens)	PF00069 (Pkinase)	4	GLY A 31 GLY A 33 VAL A 38 LYS A 53	None	0.39A	5j5xA-1tkiA: 18.5	5j5xA-1tkiA: 25.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1u59	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF07714 (Pkinase_Tyr)	4	GLY A 345 GLY A 347 VAL A 352 ASP A 479	STU A 100 (-3.3A) None STU A 100 (-4.8A) STU A 100 (-3.5A)	0.38A	5j5xA-1u59A: 24.2	5j5xA-1u59A: 22.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1u59	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF07714 (Pkinase_Tyr)	4	GLY A 345 GLY A 347 VAL A 352 LYS A 369	STU A 100 (-3.3A) None STU A 100 (-4.8A) STU A 100 ( 4.7A)	0.39A	5j5xA-1u59A: 24.2	5j5xA-1u59A: 22.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1u5q	SERINE/THREONINE PROTEIN KINASE TAO2 (Rattus norvegicus)	PF00069 (Pkinase)	4	GLY A 35 VAL A 42 LYS A 57 ASP A 169	None	0.46A	5j5xA-1u5qA: 28.1	5j5xA-1u5qA: 25.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1zrz	PROTEIN KINASE C, IOTA (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	4	GLY A 252 GLY A 254 VAL A 259 LYS A 274	BI1 A1000 (-3.6A) None BI1 A1000 (-4.2A) BI1 A1000 (-3.5A)	0.30A	5j5xA-1zrzA: 36.0	5j5xA-1zrzA: 34.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	PF00069 (Pkinase)	5	GLY B 274 GLY B 276 VAL B 281 LYS B 296 ASP B 432	None	0.71A	5j5xA-2a1aB: 23.1	5j5xA-2a1aB: 25.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2a2a	DEATH-ASSOCIATED PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	4	GLY A 20 GLY A 22 VAL A 27 LYS A 42	None	0.42A	5j5xA-2a2aA: 28.3	5j5xA-2a2aA: 27.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2csn	CASEIN KINASE-1 (Schizosaccharomyces pombe)	PF00069 (Pkinase)	4	GLY A 19 GLY A 21 SER A 22 LYS A 41	CKI A 300 ( 3.8A) None None None	0.43A	5j5xA-2csnA: 23.7	5j5xA-2csnA: 21.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	4	GLY X 18 VAL X 25 LYS X 39 ASP X 148	STU X 902 ( 3.7A) STU X 902 ( 4.8A) STU X 902 (-3.1A) STU X 902 (-3.6A)	0.35A	5j5xA-2dq7X: 25.6	5j5xA-2dq7X: 23.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2eu9	DUAL SPECIFICITY PROTEIN KINASE CLK3 (Homo sapiens)	PF00069 (Pkinase)	5	GLY A 163 GLY A 165 VAL A 170 LYS A 186 ASP A 320	None	0.64A	5j5xA-2eu9A: 25.5	5j5xA-2eu9A: 23.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2f9g	MITOGEN-ACTIVATED PROTEIN KINASE FUS3 (Saccharomyces cerevisiae)	PF00069 (Pkinase)	5	GLY A 20 GLY A 22 VAL A 27 LYS A 42 ASP A 155	ADP A 500 ( 4.1A) ADP A 500 ( 4.6A) ADP A 500 (-4.3A) ADP A 500 (-2.9A) ADP A 500 ( 2.9A)	0.66A	5j5xA-2f9gA: 26.0	5j5xA-2f9gA: 26.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2gcd	SERINE/THREONINE-PRO TEIN KINASE TAO2 (Rattus norvegicus)	PF00069 (Pkinase)	4	GLY A 35 GLY A 37 SER A 38 VAL A 42	STU A 400 (-3.3A) None None STU A 400 ( 4.8A)	0.49A	5j5xA-2gcdA: 28.1	5j5xA-2gcdA: 26.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hk5	TYROSINE-PROTEIN KINASE HCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	4	GLY A 252 GLY A 254 VAL A 259 LYS A 273	None None 1BM A 499 ( 4.8A) 1BM A 499 (-3.8A)	0.39A	5j5xA-2hk5A: 17.8	5j5xA-2hk5A: 23.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hw6	MAP KINASE-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	4	GLY A 56 GLY A 58 VAL A 63 LYS A 78	None	0.28A	5j5xA-2hw6A: 22.5	5j5xA-2hw6A: 28.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	4	GLY A 249 GLY A 251 VAL A 256 LYS A 271	None None GIN A 600 ( 4.7A) GIN A 600 (-3.6A)	0.48A	5j5xA-2hz0A: 23.1	5j5xA-2hz0A: 24.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2iwi	SERINE/THREONINE-PRO TEIN KINASE PIM-2 (Homo sapiens)	PF00069 (Pkinase)	4	GLY A 39 GLY A 41 VAL A 46 ASP A 182	HB1 A1289 (-3.1A) None HB1 A1289 (-3.6A) HB1 A1289 (-4.2A)	0.45A	5j5xA-2iwiA: 21.3	5j5xA-2iwiA: 24.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2jam	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE 1G (Homo sapiens)	PF00069 (Pkinase)	4	GLY A 30 GLY A 32 VAL A 37 LYS A 52	None None J60 A1305 (-4.8A) EDO A1304 ( 2.9A)	0.31A	5j5xA-2jamA: 19.7	5j5xA-2jamA: 30.46
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2jc6	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE 1D (Homo sapiens)	PF00069 (Pkinase)	4	GLY A 30 GLY A 32 VAL A 37 LYS A 52	QPP A1314 ( 3.7A) None QPP A1314 ( 4.6A) None	0.30A	5j5xA-2jc6A: 22.9	5j5xA-2jc6A: 31.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2qr7	RIBOSOMAL PROTEIN S6 KINASE ALPHA-3 (Mus musculus)	PF00069 (Pkinase)	4	GLY A 429 GLY A 431 LYS A 451 ASP A 561	None	0.28A	5j5xA-2qr7A: 22.8	5j5xA-2qr7A: 31.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2v55	RHO-ASSOCIATED PROTEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	4	GLY A 83 GLY A 85 VAL A 90 LYS A 105	ANP A1480 ( 4.3A) ANP A1480 ( 3.8A) None ANP A1480 (-3.4A)	0.41A	5j5xA-2v55A: 25.0	5j5xA-2v55A: 35.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2w4o	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE IV (Homo sapiens)	PF00069 (Pkinase)	4	GLY A 53 GLY A 55 VAL A 60 LYS A 75	DKI A1338 (-3.3A) None DKI A1338 (-4.2A) None	0.35A	5j5xA-2w4oA: 22.5	5j5xA-2w4oA: 29.87
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2wtk	SERINE/THREONINE-PRO TEIN KINASE 11 (Homo sapiens)	PF00069 (Pkinase)	5	GLY C 56 GLY C 58 SER C 59 VAL C 63 LYS C 78	ANP C 2 (-3.3A) ANP C 2 (-3.0A) None ANP C 2 (-4.2A) ANP C 2 (-3.6A)	0.79A	5j5xA-2wtkC: 29.9	5j5xA-2wtkC: 28.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2xyu	EPHRIN TYPE-A RECEPTOR 4, (Mus musculus)	PF07714 (Pkinase_Tyr)	4	GLY A 628 GLY A 630 VAL A 635 LYS A 653	None None Q9G A1898 ( 4.7A) Q9G A1898 (-4.8A)	0.33A	5j5xA-2xyuA: 21.8	5j5xA-2xyuA: 24.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2z2w	WEE1-LIKE PROTEIN KINASE (Homo sapiens)	PF00069 (Pkinase)	4	GLY A 306 GLY A 308 VAL A 313 ASP A 463	770 A 901 ( 4.6A) None 770 A 901 ( 4.7A) 770 A 901 (-3.8A)	0.48A	5j5xA-2z2wA: 19.1	5j5xA-2z2wA: 23.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3bqr	DEATH-ASSOCIATED PROTEIN KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	5	GLY A 20 GLY A 22 VAL A 27 LYS A 42 ASP A 161	4RB A 401 (-3.6A) None 4RB A 401 ( 4.4A) 4RB A 401 ( 2.8A) GOL A 503 ( 3.1A)	0.78A	5j5xA-3bqrA: 26.0	5j5xA-3bqrA: 26.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3c0i	PERIPHERAL PLASMA MEMBRANE PROTEIN CASK (Homo sapiens)	PF00069 (Pkinase)	4	GLY A 19 GLY A 21 VAL A 26 LYS A 41	None None 3AM A 338 ( 4.1A) 3AM A 338 (-2.9A)	0.25A	5j5xA-3c0iA: 20.3	5j5xA-3c0iA: 28.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	GLY A 202 GLY A 204 VAL A 209 LYS A 222 ASP A 332	None	0.76A	5j5xA-3d7uA: 24.4	5j5xA-3d7uA: 23.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3e7o	MITOGEN-ACTIVATED PROTEIN KINASE 9 (Homo sapiens)	PF00069 (Pkinase)	4	GLY A 33 GLY A 35 VAL A 40 LYS A 55	35F A 1 ( 4.8A) None 35F A 1 ( 4.8A) 35F A 1 ( 4.6A)	0.33A	5j5xA-3e7oA: 23.2	5j5xA-3e7oA: 26.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mdy	BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (Homo sapiens)	PF07714 (Pkinase_Tyr) PF08515 (TGF_beta_GS)	4	GLY A 211 VAL A 218 LYS A 231 ASP A 350	LDN A 1 ( 4.7A) LDN A 1 ( 4.8A) None LDN A 1 (-3.9A)	0.41A	5j5xA-3mdyA: 22.8	5j5xA-3mdyA: 21.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3mvj	CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA (Homo sapiens)	PF00069 (Pkinase)	5	GLY A 50 GLY A 52 SER A 53 VAL A 57 LYS A 72	XFE A 351 ( 4.0A) None None XFE A 351 ( 4.5A) None	0.70A	5j5xA-3mvjA: 53.1	5j5xA-3mvjA: 94.61
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3mvj	CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA (Homo sapiens)	PF00069 (Pkinase)	4	GLY A 50 VAL A 57 LYS A 72 ASP A 184	XFE A 351 ( 4.0A) XFE A 351 ( 4.5A) None None	0.39A	5j5xA-3mvjA: 53.1	5j5xA-3mvjA: 94.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3my0	SERINE/THREONINE-PRO TEIN KINASE RECEPTOR R3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	4	GLY A 209 GLY A 211 VAL A 216 LYS A 229	None None LDN A 600 (-4.5A) LDN A 600 (-4.0A)	0.25A	5j5xA-3my0A: 22.1	5j5xA-3my0A: 21.24
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3o96	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	PF00069 (Pkinase) PF00169 (PH)	4	GLY A 157 GLY A 159 VAL A 164 LYS A 179	GLY A 157 ( 0.0A) GLY A 159 ( 0.0A) VAL A 164 ( 0.6A) LYS A 179 ( 0.0A)	0.41A	5j5xA-3o96A: 29.5	5j5xA-3o96A: 34.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3pfq	PROTEIN KINASE C BETA TYPE (Rattus norvegicus)	PF00069 (Pkinase) PF00130 (C1_1) PF00168 (C2) PF00433 (Pkinase_C)	5	GLY A 349 GLY A 351 SER A 352 VAL A 356 LYS A 371	ANP A 800 ( 4.3A) None None ANP A 800 ( 4.7A) ANP A 800 (-3.3A)	1.26A	5j5xA-3pfqA: 29.6	5j5xA-3pfqA: 24.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3pfq	PROTEIN KINASE C BETA TYPE (Rattus norvegicus)	PF00069 (Pkinase) PF00130 (C1_1) PF00168 (C2) PF00433 (Pkinase_C)	5	GLY A 349 SER A 352 VAL A 356 LYS A 371 ASP A 484	ANP A 800 ( 4.3A) None ANP A 800 ( 4.7A) ANP A 800 (-3.3A) ANP A 800 (-3.0A)	0.94A	5j5xA-3pfqA: 29.6	5j5xA-3pfqA: 24.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3pp0	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	4	GLY A 727 VAL A 734 LYS A 753 ASP A 863	None 03Q A 1 (-4.5A) 03Q A 1 (-4.7A) 03Q A 1 (-4.0A)	0.45A	5j5xA-3pp0A: 24.1	5j5xA-3pp0A: 23.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3ppz	SERINE/THREONINE-PRO TEIN KINASE CTR1 (Arabidopsis thaliana)	PF07714 (Pkinase_Tyr)	5	GLY A 558 GLY A 560 VAL A 565 LYS A 578 ASP A 694	STU A 1 (-3.2A) None STU A 1 (-4.9A) STU A 1 (-3.5A) STU A 1 (-3.5A)	0.84A	5j5xA-3ppzA: 26.1	5j5xA-3ppzA: 26.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3txo	PROTEIN KINASE C ETA TYPE (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	5	GLY A 362 GLY A 364 SER A 365 VAL A 369 LYS A 384	07U A 1 ( 4.2A) None None 07U A 1 (-4.8A) 07U A 1 (-3.0A)	0.72A	5j5xA-3txoA: 24.5	5j5xA-3txoA: 39.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3txo	PROTEIN KINASE C ETA TYPE (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	5	GLY A 362 GLY A 364 VAL A 369 LYS A 384 ASP A 497	07U A 1 ( 4.2A) None 07U A 1 (-4.8A) 07U A 1 (-3.0A) 07U A 1 (-3.6A)	0.58A	5j5xA-3txoA: 24.5	5j5xA-3txoA: 39.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3uto	TWITCHIN (Caenorhabditis elegans)	PF00041 (fn3) PF00069 (Pkinase) PF07679 (I-set)	4	GLY A 163 GLY A 165 VAL A 170 LYS A 185	None	0.36A	5j5xA-3utoA: 24.9	5j5xA-3utoA: 22.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3vid	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	4	GLY A 841 GLY A 843 VAL A 848 LYS A 868	4TT A2001 ( 4.8A) None 4TT A2001 ( 4.5A) None	0.44A	5j5xA-3vidA: 20.5	5j5xA-3vidA: 22.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	PF00069 (Pkinase)	5	GLY A 60 GLY A 62 VAL A 67 LYS A 82 ASP A 197	ANK A 401 (-3.4A) ANK A 401 ( 4.9A) ANK A 401 (-4.3A) ANK A 401 (-2.4A) MG A 402 ( 2.8A)	1.04A	5j5xA-3vn9A: 17.5	5j5xA-3vn9A: 26.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3zdu	CYCLIN-DEPENDENT KINASE-LIKE 3 (Homo sapiens)	PF00069 (Pkinase)	5	GLY A 11 GLY A 13 VAL A 18 LYS A 33 ASP A 143	38R A 350 ( 3.9A) None 38R A 350 ( 4.8A) 38R A 350 (-2.9A) NA A 353 ( 2.5A)	0.54A	5j5xA-3zduA: 25.3	5j5xA-3zduA: 31.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	PF00069 (Pkinase)	4	GLY A 11 GLY A 13 VAL A 18 LYS A 33	D15 A 500 (-3.8A) D15 A 500 (-3.6A) D15 A 500 (-4.6A) D15 A 500 ( 4.1A)	0.41A	5j5xA-4aguA: 26.3	5j5xA-4aguA: 24.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4aw2	SERINE/THREONINE-PRO TEIN KINASE MRCK ALPHA (Rattus norvegicus)	PF00069 (Pkinase) PF00433 (Pkinase_C)	5	GLY A 84 GLY A 86 VAL A 91 LYS A 106 ASP A 219	None None None EDO A1419 (-3.3A) None	0.54A	5j5xA-4aw2A: 36.0	5j5xA-4aw2A: 31.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4bgq	CYCLIN-DEPENDENT KINASE-LIKE 5 (Homo sapiens)	PF00069 (Pkinase)	4	GLY A 20 GLY A 22 VAL A 27 LYS A 42	None None 38R A1000 ( 4.8A) 38R A1000 (-3.4A)	0.44A	5j5xA-4bgqA: 25.2	5j5xA-4bgqA: 25.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4bvu	PROTEIN KINASE OSPG (Shigella flexneri)	no annotation	4	GLY A 34 GLY A 36 SER A 37 LYS A 53	None	0.39A	5j5xA-4bvuA: 9.3	5j5xA-4bvuA: 20.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4c02	ACTIVIN RECEPTOR TYPE-1 (Homo sapiens)	PF00069 (Pkinase) PF08515 (TGF_beta_GS)	5	GLY A 215 GLY A 217 VAL A 222 LYS A 235 ASP A 354	None None TAK A1507 (-4.7A) TAK A1507 ( 4.5A) TAK A1507 (-3.5A)	0.82A	5j5xA-4c02A: 22.9	5j5xA-4c02A: 21.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4c0t	LIKELY PROTEIN KINASE (Candida albicans)	PF00069 (Pkinase)	4	GLY A 247 GLY A 249 VAL A 254 LYS A 269	None	0.34A	5j5xA-4c0tA: 30.5	5j5xA-4c0tA: 18.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ckr	EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	4	GLY A 617 GLY A 619 VAL A 624 LYS A 655	None None DI1 A1000 (-4.8A) DI1 A1000 (-3.9A)	0.33A	5j5xA-4ckrA: 21.3	5j5xA-4ckrA: 24.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4e7w	GLYCOGEN SYNTHASE KINASE 3 (Ustilago maydis)	PF00069 (Pkinase)	5	GLY A 45 GLY A 47 VAL A 52 LYS A 66 ASP A 181	None	0.55A	5j5xA-4e7wA: 24.4	5j5xA-4e7wA: 27.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4euu	SERINE/THREONINE-PRO TEIN KINASE TBK1 (Homo sapiens)	PF00069 (Pkinase)	4	GLY A 16 GLY A 18 VAL A 23 LYS A 38	BX7 A 401 ( 3.8A) BX7 A 401 (-3.7A) BX7 A 401 ( 4.6A) BX7 A 401 (-3.5A)	0.42A	5j5xA-4euuA: 19.9	5j5xA-4euuA: 26.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4f99	CELL DIVISION CYCLE 7-RELATED PROTEIN KINASE (Homo sapiens)	PF00069 (Pkinase)	4	GLY A 65 GLY A 67 VAL A 72 LYS A 90	ADP A 601 ( 3.8A) ADP A 601 (-3.7A) ADP A 601 (-4.0A) ADP A 601 (-2.6A)	0.39A	5j5xA-4f99A: 17.0	5j5xA-4f99A: 26.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fr4	SERINE/THREONINE-PRO TEIN KINASE 32A (Homo sapiens)	PF00069 (Pkinase)	4	GLY A 30 GLY A 32 SER A 33 ASP A 164	STU A 401 (-3.3A) None None STU A 401 ( 3.9A)	0.48A	5j5xA-4fr4A: 32.1	5j5xA-4fr4A: 29.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4gl9	TYROSINE-PROTEIN KINASE (Mus musculus)	PF07714 (Pkinase_Tyr)	4	GLY A 856 VAL A 863 LYS A 882 ASP A 994	IZA A2001 ( 4.9A) None IZA A2001 ( 4.7A) IZA A2001 ( 4.5A)	0.37A	5j5xA-4gl9A: 23.8	5j5xA-4gl9A: 25.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	5	GLY A 157 GLY A 159 VAL A 164 LYS A 179 ASP A 292	GOL A 505 ( 3.4A) 0XZ A 501 (-4.1A) 0XZ A 501 (-4.5A) GOL A 503 ( 2.8A) 0XZ A 501 ( 3.4A)	0.66A	5j5xA-4gv1A: 41.3	5j5xA-4gv1A: 38.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4jrn	RHOPTRY KINASE FAMILY PROTEIN (Toxoplasma gondii)	PF14531 (Kinase-like)	4	GLY A 259 GLY A 261 VAL A 266 LYS A 281	ANP A 601 (-3.4A) ANP A 601 ( 3.3A) ANP A 601 (-4.1A) ANP A 601 (-3.2A)	0.49A	5j5xA-4jrnA: 19.3	5j5xA-4jrnA: 23.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4k33	FIBROBLAST GROWTH FACTOR RECEPTOR 3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	GLY A 479 GLY A 481 VAL A 486 LYS A 508 ASP A 635	ACP A 801 (-3.4A) ACP A 801 (-3.6A) ACP A 801 (-4.2A) ACP A 801 (-2.7A) MG A 802 ( 3.0A)	0.69A	5j5xA-4k33A: 18.6	5j5xA-4k33A: 25.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4otd	SERINE/THREONINE-PRO TEIN KINASE N1 (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	5	GLY A 628 GLY A 630 VAL A 635 LYS A 650 ASP A 764	None	0.64A	5j5xA-4otdA: 39.6	5j5xA-4otdA: 37.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4pwn	SERINE/THREONINE-PRO TEIN KINASE WNK1 (Homo sapiens)	PF00069 (Pkinase)	5	GLY A 228 GLY A 230 SER A 231 PHE A 232 VAL A 235	None	0.59A	5j5xA-4pwnA: 22.4	5j5xA-4pwnA: 25.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4q9z	HUMAN PROTEIN KINASE C THETA (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	5	GLY A 387 GLY A 389 SER A 390 VAL A 394 LYS A 409	PZW A 801 ( 3.8A) None None PZW A 801 (-4.6A) None	0.82A	5j5xA-4q9zA: 39.0	5j5xA-4q9zA: 37.43
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ra4	PROTEIN KINASE C (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	5	GLY A 346 GLY A 348 SER A 349 VAL A 353 LYS A 368	3KZ A 701 (-3.3A) None None 3KZ A 701 (-3.9A) 3KZ A 701 ( 4.7A)	0.64A	5j5xA-4ra4A: 37.6	5j5xA-4ra4A: 36.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4rew	5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-1 (Homo sapiens)	PF00069 (Pkinase) PF16579 (AdenylateSensor)	4	GLY A 25 VAL A 32 LYS A 47 ASP A 159	STU A 601 (-3.5A) STU A 601 ( 4.8A) STU A 601 ( 3.7A) STU A 601 (-3.7A)	0.46A	5j5xA-4rewA: 31.0	5j5xA-4rewA: 23.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4wb7	DNAJ HOMOLOG SUBFAMILY B MEMBER 1,CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA (Homo sapiens)	PF00069 (Pkinase) PF00226 (DnaJ)	4	GLY A 105 VAL A 112 LYS A 127 ASP A 239	ATP A 501 (-3.5A) ATP A 501 (-4.0A) ATP A 501 (-2.6A) ZN A 503 (-1.9A)	0.43A	5j5xA-4wb7A: 52.5	5j5xA-4wb7A: 84.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wbo	RHODOPSIN KINASE (Bos taurus)	PF00069 (Pkinase) PF00615 (RGS)	5	GLY A 194 GLY A 196 VAL A 201 LYS A 216 ASP A 332	None	0.76A	5j5xA-4wboA: 29.1	5j5xA-4wboA: 27.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4xuf	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	4	GLY A 617 GLY A 619 VAL A 624 LYS A 644	None None P30 A1001 ( 4.8A) P30 A1001 ( 4.0A)	0.42A	5j5xA-4xufA: 14.9	5j5xA-4xufA: 24.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4yff	SERINE/THREONINE-PRO TEIN KINASE TNNI3K (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	GLY A 470 GLY A 472 VAL A 477 LYS A 490 ASP A 606	4CV A 801 ( 3.9A) None None 4CV A 801 (-3.9A) 4CV A 801 (-3.5A)	0.48A	5j5xA-4yffA: 15.1	5j5xA-4yffA: 24.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ylj	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 1A (Homo sapiens)	PF00069 (Pkinase)	5	GLY A 166 GLY A 168 SER A 169 VAL A 173 LYS A 188	4E1 A 505 (-3.5A) 4E1 A 505 ( 4.9A) None 4E1 A 505 (-4.5A) 4E1 A 505 (-2.7A)	0.55A	5j5xA-4yljA: 25.2	5j5xA-4yljA: 25.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5es1	MAP/MICROTUBULE AFFINITY-REGULATING KINASE 4 (Homo sapiens)	PF00069 (Pkinase) PF00627 (UBA)	5	GLY A 63 GLY A 65 VAL A 70 LYS A 85 ASP A 196	5RC A4000 ( 4.3A) 5RC A4000 ( 3.9A) 5RC A4000 (-4.6A) 5RC A4000 (-2.8A) 5RC A4000 (-3.6A)	0.57A	5j5xA-5es1A: 28.4	5j5xA-5es1A: 32.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5fd2	SERINE/THREONINE-PRO TEIN KINASE B-RAF (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	GLY A 464 GLY A 466 VAL A 471 LYS A 483 ASP A 594	None None 5XJ A 801 (-4.6A) 5XJ A 801 (-3.8A) None	0.52A	5j5xA-5fd2A: 16.0	5j5xA-5fd2A: 25.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5fm2	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET (Homo sapiens)	PF07714 (Pkinase_Tyr)	4	GLY A 731 GLY A 733 VAL A 738 LYS A 758	PP1 A2012 ( 3.9A) None PP1 A2012 (-4.4A) PP1 A2012 (-4.1A)	0.44A	5j5xA-5fm2A: 24.4	5j5xA-5fm2A: 26.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5idn	CYCLIN-DEPENDENT KINASE 8 (Homo sapiens)	PF00069 (Pkinase)	4	GLY A 28 GLY A 30 VAL A 35 LYS A 52	6A7 A 401 (-3.6A) None 6A7 A 401 ( 4.5A) 6A7 A 401 ( 2.9A)	0.40A	5j5xA-5idnA: 23.7	5j5xA-5idnA: 25.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ig1	CAMK/CAMK2 PROTEIN KINASE (Salpingoeca rosetta)	PF00069 (Pkinase)	4	GLY A 25 GLY A 27 VAL A 32 LYS A 47	None	0.41A	5j5xA-5ig1A: 28.6	5j5xA-5ig1A: 28.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5j5t	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	4	GLY A 23 VAL A 30 LYS A 45 ASP A 154	None 6G2 A 901 ( 4.9A) 6G2 A 901 ( 3.9A) 6G2 A 901 (-3.4A)	0.39A	5j5xA-5j5tA: 23.6	5j5xA-5j5tA: 25.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5j9z	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	4	GLY A 719 GLY A 721 VAL A 726 LYS A 745	6HJ A1101 ( 4.2A) None 6HJ A1101 ( 4.7A) 6HJ A1101 (-4.2A)	0.41A	5j5xA-5j9zA: 22.6	5j5xA-5j9zA: 24.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5lpz	PROTEIN BRASSINOSTEROID INSENSITIVE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	5	GLY A 890 GLY A 892 VAL A 897 LYS A 911 ASP A1027	ADP A1200 ( 4.0A) None ADP A1200 (-4.4A) ADP A1200 ( 4.3A) ADP A1200 (-3.4A)	0.82A	5j5xA-5lpzA: 22.3	5j5xA-5lpzA: 27.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5lxd	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	5	GLY A 156 GLY A 158 SER A 159 VAL A 163 LYS A 178	7A7 A 501 (-3.2A) None None 7A7 A 501 (-4.4A) 7A7 A 501 (-3.5A)	0.63A	5j5xA-5lxdA: 25.1	5j5xA-5lxdA: 26.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5lxd	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	5	GLY A 156 GLY A 158 VAL A 163 LYS A 178 ASP A 295	7A7 A 501 (-3.2A) None 7A7 A 501 (-4.4A) 7A7 A 501 (-3.5A) 7A7 A 501 (-3.2A)	0.51A	5j5xA-5lxdA: 25.1	5j5xA-5lxdA: 26.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5tur	SERINE/THREONINE-PRO TEIN KINASE PIM-1 (Homo sapiens)	no annotation	5	GLY A 45 GLY A 47 VAL A 52 LYS A 67 ASP A 186	None None 7LK A 401 (-4.9A) None None	0.85A	5j5xA-5turA: 28.9	5j5xA-5turA: 23.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5u7q	RHO-ASSOCIATED PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	5	GLY A 99 GLY A 101 VAL A 106 LYS A 121 ASP A 232	None	0.85A	5j5xA-5u7qA: 36.5	5j5xA-5u7qA: 34.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5u94	SERINE/THREONINE-PRO TEIN KINASE PKNB (Mycobacterium tuberculosis)	no annotation	5	GLY A 18 GLY A 20 VAL A 25 LYS A 40 ASP A 156	G93 A 301 ( 3.2A) None G93 A 301 (-3.4A) G93 A 301 (-3.0A) G93 A 301 ( 3.2A)	0.61A	5j5xA-5u94A: 27.6	5j5xA-5u94A: 13.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	PF00069 (Pkinase)	5	GLY A 117 GLY A 119 SER A 120 VAL A 124 LYS A 139	H8H A 401 ( 3.7A) None None H8H A 401 (-4.7A) H8H A 401 (-4.9A)	0.66A	5j5xA-5vcxA: 24.1	5j5xA-5vcxA: 26.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5xv7	SERINE-ARGININE (SR) PROTEIN KINASE 1 (Homo sapiens)	no annotation	4	GLY A 87 GLY A 89 VAL A 94 LYS A 109	EMH A 705 ( 3.9A) None EMH A 705 ( 4.4A) EMH A 705 ( 4.8A)	0.49A	5j5xA-5xv7A: 23.8	5j5xA-5xv7A: 10.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5xzw	SERINE/THREONINE-PRO TEIN KINASE RAD53 (Saccharomyces cerevisiae)	no annotation	4	GLY A 205 GLY A 207 VAL A 212 LYS A 227	None	0.47A	5j5xA-5xzwA: 22.4	5j5xA-5xzwA: 24.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5y86	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 3 (Homo sapiens)	no annotation	5	GLY A 216 GLY A 218 VAL A 223 LYS A 238 ASP A 355	None PO4 A 602 (-3.5A) HRM A 601 ( 4.9A) HRM A 601 (-3.3A) HRM A 601 (-4.7A)	0.72A	5j5xA-5y86A: 24.8	5j5xA-5y86A: 12.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6b4w	DUAL SPECIFICITY PROTEIN KINASE TTK (Homo sapiens)	no annotation	4	GLY A 532 GLY A 534 VAL A 539 LYS A 553	CQ7 A 801 ( 4.0A) None CQ7 A 801 ( 4.8A) CQ7 A 801 (-3.2A)	0.43A	5j5xA-6b4wA: 23.4	5j5xA-6b4wA: 24.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6bql	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE KINASE 2 (Homo sapiens)	no annotation	5	GLY A 172 GLY A 174 SER A 175 VAL A 179 LYS A 194	BI9 A 501 (-3.6A) None ACT A 504 (-3.3A) BI9 A 501 ( 4.8A) NH4 A 506 ( 4.4A)	0.46A	5j5xA-6bqlA: 29.4	5j5xA-6bqlA: 13.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6c0t	CGMP-DEPENDENT PROTEIN KINASE 1 (Homo sapiens)	no annotation	4	GLY A 367 GLY A 369 VAL A 374 LYS A 390	EE4 A 701 (-3.9A) EE4 A 701 (-3.4A) EE4 A 701 (-4.4A) DMS A 702 (-3.5A)	0.29A	5j5xA-6c0tA: 41.6	5j5xA-6c0tA: 18.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6c9d	SERINE/THREONINE-PRO TEIN KINASE MARK1,SERINE/THREONI NE-PROTEIN KINASE MARK1 (Homo sapiens)	no annotation	5	GLY A 67 GLY A 69 PHE A 71 VAL A 74 LYS A 89	None	0.69A	5j5xA-6c9dA: 30.1	5j5xA-6c9dA: 13.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6c9d	SERINE/THREONINE-PRO TEIN KINASE MARK1,SERINE/THREONI NE-PROTEIN KINASE MARK1 (Homo sapiens)	no annotation	5	GLY A 67 GLY A 69 VAL A 74 LYS A 89 ASP A 200	None	0.51A	5j5xA-6c9dA: 30.1	5j5xA-6c9dA: 13.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6ccf	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE KINASE 1 (Homo sapiens)	no annotation	5	GLY A 135 GLY A 137 VAL A 142 LYS A 157 ASP A 293	H1N A 501 ( 3.8A) None H1N A 501 (-4.4A) H1N A 501 (-2.8A) H1N A 501 (-3.5A)	0.78A	5j5xA-6ccfA: 28.4	5j5xA-6ccfA: 13.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6fyl	DUAL SPECIFICITY PROTEIN KINASE CLK2 (Homo sapiens)	no annotation	4	GLY A 170 GLY A 172 VAL A 177 LYS A 193	3NG A 501 (-3.5A) 3NG A 501 ( 4.5A) 3NG A 501 ( 4.4A) 3NG A 501 (-3.0A)	0.34A	5j5xA-6fylA: 25.1	5j5xA-6fylA: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6fyo	DUAL SPECIFICITY PROTEIN KINASE CLK1 (Homo sapiens)	no annotation	5	GLY A 168 GLY A 170 VAL A 175 LYS A 191 ASP A 325	None None None EAQ A 501 (-3.2A) EAQ A 501 (-4.6A)	0.70A	5j5xA-6fyoA: 25.7	5j5xA-6fyoA: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6fyv	DUAL SPECIFICITY PROTEIN KINASE CLK4 (Homo sapiens)	no annotation	5	GLY A 168 GLY A 170 VAL A 175 LYS A 191 ASP A 325	3NG A 501 (-3.5A) 3NG A 501 ( 4.9A) 3NG A 501 ( 4.3A) 3NG A 501 (-2.7A) 3NG A 501 (-4.3A)	0.68A	5j5xA-6fyvA: 25.6	5j5xA-6fyvA: undetectable

[["5J5X_B_AZ1B2_1","1gng","Homo sapiens","GLYCOGEN SYNTHASE KINASE-3 BETA","PF00069(Pkinase)",6,"GLY A  63;GLY A  65;SER A  66;VAL A  70;LYS A  85;ASP A 200","None","0.56A","5j5xA-1gngA:25.1","5j5xA-1gngA:23.50"],["5J5X_B_AZ1B2_1","1gzk","Homo sapiens","RAC-BETA SERINE\/THREONINE PROTEIN KINASE","PF00069(Pkinase);PF00433(Pkinase_C)",4,"GLY A 159;GLY A 161;VAL A 166;LYS A 181","None","0.37A","5j5xA-1gzkA:31.0","5j5xA-1gzkA:39.60"],["5J5X_B_AZ1B2_1","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",5,"GLY A 202;GLY A 204;VAL A 209;LYS A 222;ASP A 332","None","0.76A","5j5xA-1k9aA:24.3","5j5xA-1k9aA:21.47"],["5J5X_B_AZ1B2_1","1kob","Aplysia californica","TWITCHIN","PF00069(Pkinase)",4,"GLY A  60;GLY A  62;VAL A  67;LYS A  82","None","0.40A","5j5xA-1kobA:24.6","5j5xA-1kobA:26.72"],["5J5X_B_AZ1B2_1","1m2p","Zea mays","CASEIN KINASE II, ALPHA CHAIN","PF00069(Pkinase)",4,"GLY A  46;GLY A  48;VAL A  53;LYS A  68","HNA A 351 (-2.8A);HNA A 351 ( 4.6A);HNA A 351 (-4.5A);HNA A 351 (-2.6A)","0.43A","5j5xA-1m2pA:24.5","5j5xA-1m2pA:23.99"],["5J5X_B_AZ1B2_1","1nxk","Homo sapiens","MAP KINASE-ACTIVATED PROTEIN KINASE 2","PF00069(Pkinase)",4,"GLY A  71;VAL A  78;LYS A  93;ASP A 207","STU A 401 (-3.6A);STU A 401 (-4.7A);STU A 401 ( 4.5A);STU A 401 (-3.6A)","0.42A","5j5xA-1nxkA:21.9","5j5xA-1nxkA:28.30"],["5J5X_B_AZ1B2_1","1tki","Homo sapiens","TITIN","PF00069(Pkinase)",4,"GLY A  31;GLY A  33;VAL A  38;LYS A  53","None","0.39A","5j5xA-1tkiA:18.5","5j5xA-1tkiA:25.69"],["5J5X_B_AZ1B2_1","1u59","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF07714(Pkinase_Tyr)",4,"GLY A 345;GLY A 347;VAL A 352;ASP A 479","STU A 100 (-3.3A);None;STU A 100 (-4.8A);STU A 100 (-3.5A)","0.38A","5j5xA-1u59A:24.2","5j5xA-1u59A:22.25"],["5J5X_B_AZ1B2_1","1u59","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF07714(Pkinase_Tyr)",4,"GLY A 345;GLY A 347;VAL A 352;LYS A 369","STU A 100 (-3.3A);None;STU A 100 (-4.8A);STU A 100 ( 4.7A)","0.39A","5j5xA-1u59A:24.2","5j5xA-1u59A:22.25"],["5J5X_B_AZ1B2_1","1u5q","Rattus norvegicus","SERINE\/THREONINE PROTEIN KINASE TAO2","PF00069(Pkinase)",4,"GLY A  35;VAL A  42;LYS A  57;ASP A 169","None","0.46A","5j5xA-1u5qA:28.1","5j5xA-1u5qA:25.32"],["5J5X_B_AZ1B2_1","1zrz","Homo sapiens","PROTEIN KINASE C, IOTA","PF00069(Pkinase);PF00433(Pkinase_C)",4,"GLY A 252;GLY A 254;VAL A 259;LYS A 274","BI1 A1000 (-3.6A);None;BI1 A1000 (-4.2A);BI1 A1000 (-3.5A)","0.30A","5j5xA-1zrzA:36.0","5j5xA-1zrzA:34.72"],["5J5X_B_AZ1B2_1","2a1a","Homo sapiens","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","PF00069(Pkinase)",5,"GLY B 274;GLY B 276;VAL B 281;LYS B 296;ASP B 432","None","0.71A","5j5xA-2a1aB:23.1","5j5xA-2a1aB:25.60"],["5J5X_B_AZ1B2_1","2a2a","Homo sapiens","DEATH-ASSOCIATED PROTEIN KINASE 2","PF00069(Pkinase)",4,"GLY A  20;GLY A  22;VAL A  27;LYS A  42","None","0.42A","5j5xA-2a2aA:28.3","5j5xA-2a2aA:27.53"],["5J5X_B_AZ1B2_1","2csn","Schizosaccharomyces pombe","CASEIN KINASE-1","PF00069(Pkinase)",4,"GLY A  19;GLY A  21;SER A  22;LYS A  41","CKI A 300 ( 3.8A);None;None;None","0.43A","5j5xA-2csnA:23.7","5j5xA-2csnA:21.84"],["5J5X_B_AZ1B2_1","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",4,"GLY X  18;VAL X  25;LYS X  39;ASP X 148","STU X 902 ( 3.7A);STU X 902 ( 4.8A);STU X 902 (-3.1A);STU X 902 (-3.6A)","0.35A","5j5xA-2dq7X:25.6","5j5xA-2dq7X:23.23"],["5J5X_B_AZ1B2_1","2eu9","Homo sapiens","DUAL SPECIFICITY PROTEIN KINASE CLK3","PF00069(Pkinase)",5,"GLY A 163;GLY A 165;VAL A 170;LYS A 186;ASP A 320","None","0.64A","5j5xA-2eu9A:25.5","5j5xA-2eu9A:23.70"],["5J5X_B_AZ1B2_1","2f9g","Saccharomyces cerevisiae","MITOGEN-ACTIVATED PROTEIN KINASE FUS3","PF00069(Pkinase)",5,"GLY A  20;GLY A  22;VAL A  27;LYS A  42;ASP A 155","ADP A 500 ( 4.1A);ADP A 500 ( 4.6A);ADP A 500 (-4.3A);ADP A 500 (-2.9A);ADP A 500 ( 2.9A)","0.66A","5j5xA-2f9gA:26.0","5j5xA-2f9gA:26.50"],["5J5X_B_AZ1B2_1","2gcd","Rattus norvegicus","SERINE\/THREONINE-PROTEIN KINASE TAO2","PF00069(Pkinase)",4,"GLY A  35;GLY A  37;SER A  38;VAL A  42","STU A 400 (-3.3A);None;None;STU A 400 ( 4.8A)","0.49A","5j5xA-2gcdA:28.1","5j5xA-2gcdA:26.20"],["5J5X_B_AZ1B2_1","2hk5","Homo sapiens","TYROSINE-PROTEIN KINASE HCK","PF07714(Pkinase_Tyr)",4,"GLY A 252;GLY A 254;VAL A 259;LYS A 273","None;None;1BM A 499 ( 4.8A);1BM A 499 (-3.8A)","0.39A","5j5xA-2hk5A:17.8","5j5xA-2hk5A:23.82"],["5J5X_B_AZ1B2_1","2hw6","Homo sapiens","MAP KINASE-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 1","PF00069(Pkinase)",4,"GLY A  56;GLY A  58;VAL A  63;LYS A  78","None","0.28A","5j5xA-2hw6A:22.5","5j5xA-2hw6A:28.35"],["5J5X_B_AZ1B2_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",4,"GLY A 249;GLY A 251;VAL A 256;LYS A 271","None;None;GIN A 600 ( 4.7A);GIN A 600 (-3.6A)","0.48A","5j5xA-2hz0A:23.1","5j5xA-2hz0A:24.45"],["5J5X_B_AZ1B2_1","2iwi","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PIM-2","PF00069(Pkinase)",4,"GLY A  39;GLY A  41;VAL A  46;ASP A 182","HB1 A1289 (-3.1A);None;HB1 A1289 (-3.6A);HB1 A1289 (-4.2A)","0.45A","5j5xA-2iwiA:21.3","5j5xA-2iwiA:24.79"],["5J5X_B_AZ1B2_1","2jam","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 1G","PF00069(Pkinase)",4,"GLY A  30;GLY A  32;VAL A  37;LYS A  52","None;None;J60 A1305 (-4.8A);EDO A1304 ( 2.9A)","0.31A","5j5xA-2jamA:19.7","5j5xA-2jamA:30.46"],["5J5X_B_AZ1B2_1","2jc6","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 1D","PF00069(Pkinase)",4,"GLY A  30;GLY A  32;VAL A  37;LYS A  52","QPP A1314 ( 3.7A);None;QPP A1314 ( 4.6A);None","0.30A","5j5xA-2jc6A:22.9","5j5xA-2jc6A:31.77"],["5J5X_B_AZ1B2_1","2qr7","Mus musculus","RIBOSOMAL PROTEIN S6 KINASE ALPHA-3","PF00069(Pkinase)",4,"GLY A 429;GLY A 431;LYS A 451;ASP A 561","None","0.28A","5j5xA-2qr7A:22.8","5j5xA-2qr7A:31.99"],["5J5X_B_AZ1B2_1","2v55","Homo sapiens","RHO-ASSOCIATED PROTEIN KINASE 1","PF00069(Pkinase)",4,"GLY A  83;GLY A  85;VAL A  90;LYS A 105","ANP A1480 ( 4.3A);ANP A1480 ( 3.8A);None;ANP A1480 (-3.4A)","0.41A","5j5xA-2v55A:25.0","5j5xA-2v55A:35.34"],["5J5X_B_AZ1B2_1","2w4o","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE IV","PF00069(Pkinase)",4,"GLY A  53;GLY A  55;VAL A  60;LYS A  75","DKI A1338 (-3.3A);None;DKI A1338 (-4.2A);None","0.35A","5j5xA-2w4oA:22.5","5j5xA-2w4oA:29.87"],["5J5X_B_AZ1B2_1","2wtk","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 11","PF00069(Pkinase)",5,"GLY C  56;GLY C  58;SER C  59;VAL C  63;LYS C  78","ANP C   2 (-3.3A);ANP C   2 (-3.0A);None;ANP C   2 (-4.2A);ANP C   2 (-3.6A)","0.79A","5j5xA-2wtkC:29.9","5j5xA-2wtkC:28.41"],["5J5X_B_AZ1B2_1","2xyu","Mus musculus","EPHRIN TYPE-A RECEPTOR 4,","PF07714(Pkinase_Tyr)",4,"GLY A 628;GLY A 630;VAL A 635;LYS A 653","None;None;Q9G A1898 ( 4.7A);Q9G A1898 (-4.8A)","0.33A","5j5xA-2xyuA:21.8","5j5xA-2xyuA:24.59"],["5J5X_B_AZ1B2_1","2z2w","Homo sapiens","WEE1-LIKE PROTEIN KINASE","PF00069(Pkinase)",4,"GLY A 306;GLY A 308;VAL A 313;ASP A 463","770 A 901 ( 4.6A);None;770 A 901 ( 4.7A);770 A 901 (-3.8A)","0.48A","5j5xA-2z2wA:19.1","5j5xA-2z2wA:23.18"],["5J5X_B_AZ1B2_1","3bqr","Homo sapiens","DEATH-ASSOCIATED PROTEIN KINASE 3","PF00069(Pkinase)",5,"GLY A  20;GLY A  22;VAL A  27;LYS A  42;ASP A 161","4RB A 401 (-3.6A);None;4RB A 401 ( 4.4A);4RB A 401 ( 2.8A);GOL A 503 ( 3.1A)","0.78A","5j5xA-3bqrA:26.0","5j5xA-3bqrA:26.94"],["5J5X_B_AZ1B2_1","3c0i","Homo sapiens","PERIPHERAL PLASMA MEMBRANE PROTEIN CASK","PF00069(Pkinase)",4,"GLY A  19;GLY A  21;VAL A  26;LYS A  41","None;None;3AM A 338 ( 4.1A);3AM A 338 (-2.9A)","0.25A","5j5xA-3c0iA:20.3","5j5xA-3c0iA:28.38"],["5J5X_B_AZ1B2_1","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",5,"GLY A 202;GLY A 204;VAL A 209;LYS A 222;ASP A 332","None","0.76A","5j5xA-3d7uA:24.4","5j5xA-3d7uA:23.40"],["5J5X_B_AZ1B2_1","3e7o","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE 9","PF00069(Pkinase)",4,"GLY A  33;GLY A  35;VAL A  40;LYS A  55","35F A   1 ( 4.8A);None;35F A   1 ( 4.8A);35F A   1 ( 4.6A)","0.33A","5j5xA-3e7oA:23.2","5j5xA-3e7oA:26.11"],["5J5X_B_AZ1B2_1","3mdy","Homo sapiens","BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B","PF07714(Pkinase_Tyr);PF08515(TGF_beta_GS)",4,"GLY A 211;VAL A 218;LYS A 231;ASP A 350","LDN A   1 ( 4.7A);LDN A   1 ( 4.8A);None;LDN A   1 (-3.9A)","0.41A","5j5xA-3mdyA:22.8","5j5xA-3mdyA:21.33"],["5J5X_B_AZ1B2_1","3mvj","Homo sapiens","CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA","PF00069(Pkinase)",5,"GLY A  50;GLY A  52;SER A  53;VAL A  57;LYS A  72","XFE A 351 ( 4.0A);None;None;XFE A 351 ( 4.5A);None","0.70A","5j5xA-3mvjA:53.1","5j5xA-3mvjA:94.61"],["5J5X_B_AZ1B2_1","3mvj","Homo sapiens","CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA","PF00069(Pkinase)",4,"GLY A  50;VAL A  57;LYS A  72;ASP A 184","XFE A 351 ( 4.0A);XFE A 351 ( 4.5A);None;None","0.39A","5j5xA-3mvjA:53.1","5j5xA-3mvjA:94.61"],["5J5X_B_AZ1B2_1","3my0","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE RECEPTOR R3","PF07714(Pkinase_Tyr)",4,"GLY A 209;GLY A 211;VAL A 216;LYS A 229","None;None;LDN A 600 (-4.5A);LDN A 600 (-4.0A)","0.25A","5j5xA-3my0A:22.1","5j5xA-3my0A:21.24"],["5J5X_B_AZ1B2_1","3o96","Homo sapiens","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","PF00069(Pkinase);PF00169(PH)",4,"GLY A 157;GLY A 159;VAL A 164;LYS A 179","GLY A 157 ( 0.0A);GLY A 159 ( 0.0A);VAL A 164 ( 0.6A);LYS A 179 ( 0.0A)","0.41A","5j5xA-3o96A:29.5","5j5xA-3o96A:34.20"],["5J5X_B_AZ1B2_1","3pfq","Rattus norvegicus","PROTEIN KINASE C BETA TYPE","PF00069(Pkinase);PF00130(C1_1);PF00168(C2);PF00433(Pkinase_C)",5,"GLY A 349;GLY A 351;SER A 352;VAL A 356;LYS A 371","ANP A 800 ( 4.3A);None;None;ANP A 800 ( 4.7A);ANP A 800 (-3.3A)","1.26A","5j5xA-3pfqA:29.6","5j5xA-3pfqA:24.29"],["5J5X_B_AZ1B2_1","3pfq","Rattus norvegicus","PROTEIN KINASE C BETA TYPE","PF00069(Pkinase);PF00130(C1_1);PF00168(C2);PF00433(Pkinase_C)",5,"GLY A 349;SER A 352;VAL A 356;LYS A 371;ASP A 484","ANP A 800 ( 4.3A);None;ANP A 800 ( 4.7A);ANP A 800 (-3.3A);ANP A 800 (-3.0A)","0.94A","5j5xA-3pfqA:29.6","5j5xA-3pfqA:24.29"],["5J5X_B_AZ1B2_1","3pp0","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2","PF07714(Pkinase_Tyr)",4,"GLY A 727;VAL A 734;LYS A 753;ASP A 863","None;03Q A   1 (-4.5A);03Q A   1 (-4.7A);03Q A   1 (-4.0A)","0.45A","5j5xA-3pp0A:24.1","5j5xA-3pp0A:23.04"],["5J5X_B_AZ1B2_1","3ppz","Arabidopsis thaliana","SERINE\/THREONINE-PROTEIN KINASE CTR1","PF07714(Pkinase_Tyr)",5,"GLY A 558;GLY A 560;VAL A 565;LYS A 578;ASP A 694","STU A   1 (-3.2A);None;STU A   1 (-4.9A);STU A   1 (-3.5A);STU A   1 (-3.5A)","0.84A","5j5xA-3ppzA:26.1","5j5xA-3ppzA:26.70"],["5J5X_B_AZ1B2_1","3txo","Homo sapiens","PROTEIN KINASE C ETA TYPE","PF00069(Pkinase);PF00433(Pkinase_C)",5,"GLY A 362;GLY A 364;SER A 365;VAL A 369;LYS A 384","07U A   1 ( 4.2A);None;None;07U A   1 (-4.8A);07U A   1 (-3.0A)","0.72A","5j5xA-3txoA:24.5","5j5xA-3txoA:39.23"],["5J5X_B_AZ1B2_1","3txo","Homo sapiens","PROTEIN KINASE C ETA TYPE","PF00069(Pkinase);PF00433(Pkinase_C)",5,"GLY A 362;GLY A 364;VAL A 369;LYS A 384;ASP A 497","07U A   1 ( 4.2A);None;07U A   1 (-4.8A);07U A   1 (-3.0A);07U A   1 (-3.6A)","0.58A","5j5xA-3txoA:24.5","5j5xA-3txoA:39.23"],["5J5X_B_AZ1B2_1","3uto","Caenorhabditis elegans","TWITCHIN","PF00041(fn3);PF00069(Pkinase);PF07679(I-set)",4,"GLY A 163;GLY A 165;VAL A 170;LYS A 185","None","0.36A","5j5xA-3utoA:24.9","5j5xA-3utoA:22.39"],["5J5X_B_AZ1B2_1","3vid","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",4,"GLY A 841;GLY A 843;VAL A 848;LYS A 868","4TT A2001 ( 4.8A);None;4TT A2001 ( 4.5A);None","0.44A","5j5xA-3vidA:20.5","5j5xA-3vidA:22.45"],["5J5X_B_AZ1B2_1","3vn9","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","PF00069(Pkinase)",5,"GLY A  60;GLY A  62;VAL A  67;LYS A  82;ASP A 197","ANK A 401 (-3.4A);ANK A 401 ( 4.9A);ANK A 401 (-4.3A);ANK A 401 (-2.4A); MG A 402 ( 2.8A)","1.04A","5j5xA-3vn9A:17.5","5j5xA-3vn9A:26.42"],["5J5X_B_AZ1B2_1","3zdu","Homo sapiens","CYCLIN-DEPENDENT KINASE-LIKE 3","PF00069(Pkinase)",5,"GLY A  11;GLY A  13;VAL A  18;LYS A  33;ASP A 143","38R A 350 ( 3.9A);None;38R A 350 ( 4.8A);38R A 350 (-2.9A); NA A 353 ( 2.5A)","0.54A","5j5xA-3zduA:25.3","5j5xA-3zduA:31.76"],["5J5X_B_AZ1B2_1","4agu","Homo sapiens","CYCLIN-DEPENDENT KINASE-LIKE 1","PF00069(Pkinase)",4,"GLY A  11;GLY A  13;VAL A  18;LYS A  33","D15 A 500 (-3.8A);D15 A 500 (-3.6A);D15 A 500 (-4.6A);D15 A 500 ( 4.1A)","0.41A","5j5xA-4aguA:26.3","5j5xA-4aguA:24.86"],["5J5X_B_AZ1B2_1","4aw2","Rattus norvegicus","SERINE\/THREONINE-PROTEIN KINASE MRCK ALPHA","PF00069(Pkinase);PF00433(Pkinase_C)",5,"GLY A  84;GLY A  86;VAL A  91;LYS A 106;ASP A 219","None;None;None;EDO A1419 (-3.3A);None","0.54A","5j5xA-4aw2A:36.0","5j5xA-4aw2A:31.28"],["5J5X_B_AZ1B2_1","4bgq","Homo sapiens","CYCLIN-DEPENDENT KINASE-LIKE 5","PF00069(Pkinase)",4,"GLY A  20;GLY A  22;VAL A  27;LYS A  42","None;None;38R A1000 ( 4.8A);38R A1000 (-3.4A)","0.44A","5j5xA-4bgqA:25.2","5j5xA-4bgqA:25.41"],["5J5X_B_AZ1B2_1","4bvu","Shigella flexneri","PROTEIN KINASE OSPG","no annotation",4,"GLY A  34;GLY A  36;SER A  37;LYS A  53","None","0.39A","5j5xA-4bvuA:9.3","5j5xA-4bvuA:20.36"],["5J5X_B_AZ1B2_1","4c02","Homo sapiens","ACTIVIN RECEPTOR TYPE-1","PF00069(Pkinase);PF08515(TGF_beta_GS)",5,"GLY A 215;GLY A 217;VAL A 222;LYS A 235;ASP A 354","None;None;TAK A1507 (-4.7A);TAK A1507 ( 4.5A);TAK A1507 (-3.5A)","0.82A","5j5xA-4c02A:22.9","5j5xA-4c02A:21.47"],["5J5X_B_AZ1B2_1","4c0t","Candida albicans","LIKELY PROTEIN KINASE","PF00069(Pkinase)",4,"GLY A 247;GLY A 249;VAL A 254;LYS A 269","None","0.34A","5j5xA-4c0tA:30.5","5j5xA-4c0tA:18.33"],["5J5X_B_AZ1B2_1","4ckr","Homo sapiens","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","PF07714(Pkinase_Tyr)",4,"GLY A 617;GLY A 619;VAL A 624;LYS A 655","None;None;DI1 A1000 (-4.8A);DI1 A1000 (-3.9A)","0.33A","5j5xA-4ckrA:21.3","5j5xA-4ckrA:24.24"],["5J5X_B_AZ1B2_1","4e7w","Ustilago maydis","GLYCOGEN SYNTHASE KINASE 3","PF00069(Pkinase)",5,"GLY A  45;GLY A  47;VAL A  52;LYS A  66;ASP A 181","None","0.55A","5j5xA-4e7wA:24.4","5j5xA-4e7wA:27.43"],["5J5X_B_AZ1B2_1","4euu","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE TBK1","PF00069(Pkinase)",4,"GLY A  16;GLY A  18;VAL A  23;LYS A  38","BX7 A 401 ( 3.8A);BX7 A 401 (-3.7A);BX7 A 401 ( 4.6A);BX7 A 401 (-3.5A)","0.42A","5j5xA-4euuA:19.9","5j5xA-4euuA:26.74"],["5J5X_B_AZ1B2_1","4f99","Homo sapiens","CELL DIVISION CYCLE 7-RELATED PROTEIN KINASE","PF00069(Pkinase)",4,"GLY A  65;GLY A  67;VAL A  72;LYS A  90","ADP A 601 ( 3.8A);ADP A 601 (-3.7A);ADP A 601 (-4.0A);ADP A 601 (-2.6A)","0.39A","5j5xA-4f99A:17.0","5j5xA-4f99A:26.68"],["5J5X_B_AZ1B2_1","4fr4","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 32A","PF00069(Pkinase)",4,"GLY A  30;GLY A  32;SER A  33;ASP A 164","STU A 401 (-3.3A);None;None;STU A 401 ( 3.9A)","0.48A","5j5xA-4fr4A:32.1","5j5xA-4fr4A:29.51"],["5J5X_B_AZ1B2_1","4gl9","Mus musculus","TYROSINE-PROTEIN KINASE","PF07714(Pkinase_Tyr)",4,"GLY A 856;VAL A 863;LYS A 882;ASP A 994","IZA A2001 ( 4.9A);None;IZA A2001 ( 4.7A);IZA A2001 ( 4.5A)","0.37A","5j5xA-4gl9A:23.8","5j5xA-4gl9A:25.35"],["5J5X_B_AZ1B2_1","4gv1","Homo sapiens","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","PF00069(Pkinase);PF00433(Pkinase_C)",5,"GLY A 157;GLY A 159;VAL A 164;LYS A 179;ASP A 292","GOL A 505 ( 3.4A);0XZ A 501 (-4.1A);0XZ A 501 (-4.5A);GOL A 503 ( 2.8A);0XZ A 501 ( 3.4A)","0.66A","5j5xA-4gv1A:41.3","5j5xA-4gv1A:38.24"],["5J5X_B_AZ1B2_1","4jrn","Toxoplasma gondii","RHOPTRY KINASE FAMILY PROTEIN","PF14531(Kinase-like)",4,"GLY A 259;GLY A 261;VAL A 266;LYS A 281","ANP A 601 (-3.4A);ANP A 601 ( 3.3A);ANP A 601 (-4.1A);ANP A 601 (-3.2A)","0.49A","5j5xA-4jrnA:19.3","5j5xA-4jrnA:23.75"],["5J5X_B_AZ1B2_1","4k33","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 3","PF07714(Pkinase_Tyr)",5,"GLY A 479;GLY A 481;VAL A 486;LYS A 508;ASP A 635","ACP A 801 (-3.4A);ACP A 801 (-3.6A);ACP A 801 (-4.2A);ACP A 801 (-2.7A); MG A 802 ( 3.0A)","0.69A","5j5xA-4k33A:18.6","5j5xA-4k33A:25.45"],["5J5X_B_AZ1B2_1","4otd","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE N1","PF00069(Pkinase);PF00433(Pkinase_C)",5,"GLY A 628;GLY A 630;VAL A 635;LYS A 650;ASP A 764","None","0.64A","5j5xA-4otdA:39.6","5j5xA-4otdA:37.43"],["5J5X_B_AZ1B2_1","4pwn","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE WNK1","PF00069(Pkinase)",5,"GLY A 228;GLY A 230;SER A 231;PHE A 232;VAL A 235","None","0.59A","5j5xA-4pwnA:22.4","5j5xA-4pwnA:25.00"],["5J5X_B_AZ1B2_1","4q9z","Homo sapiens","HUMAN PROTEIN KINASE C THETA","PF00069(Pkinase);PF00433(Pkinase_C)",5,"GLY A 387;GLY A 389;SER A 390;VAL A 394;LYS A 409","PZW A 801 ( 3.8A);None;None;PZW A 801 (-4.6A);None","0.82A","5j5xA-4q9zA:39.0","5j5xA-4q9zA:37.43"],["5J5X_B_AZ1B2_1","4ra4","Homo sapiens","PROTEIN KINASE C","PF00069(Pkinase);PF00433(Pkinase_C)",5,"GLY A 346;GLY A 348;SER A 349;VAL A 353;LYS A 368","3KZ A 701 (-3.3A);None;None;3KZ A 701 (-3.9A);3KZ A 701 ( 4.7A)","0.64A","5j5xA-4ra4A:37.6","5j5xA-4ra4A:36.13"],["5J5X_B_AZ1B2_1","4rew","Homo sapiens","5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-1","PF00069(Pkinase);PF16579(AdenylateSensor)",4,"GLY A  25;VAL A  32;LYS A  47;ASP A 159","STU A 601 (-3.5A);STU A 601 ( 4.8A);STU A 601 ( 3.7A);STU A 601 (-3.7A)","0.46A","5j5xA-4rewA:31.0","5j5xA-4rewA:23.10"],["5J5X_B_AZ1B2_1","4wb7","Homo sapiens","DNAJ HOMOLOG SUBFAMILY B MEMBER 1,CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA","PF00069(Pkinase);PF00226(DnaJ)",4,"GLY A 105;VAL A 112;LYS A 127;ASP A 239","ATP A 501 (-3.5A);ATP A 501 (-4.0A);ATP A 501 (-2.6A); ZN A 503 (-1.9A)","0.43A","5j5xA-4wb7A:52.5","5j5xA-4wb7A:84.94"],["5J5X_B_AZ1B2_1","4wbo","Bos taurus","RHODOPSIN KINASE","PF00069(Pkinase);PF00615(RGS)",5,"GLY A 194;GLY A 196;VAL A 201;LYS A 216;ASP A 332","None","0.76A","5j5xA-4wboA:29.1","5j5xA-4wboA:27.72"],["5J5X_B_AZ1B2_1","4xuf","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",4,"GLY A 617;GLY A 619;VAL A 624;LYS A 644","None;None;P30 A1001 ( 4.8A);P30 A1001 ( 4.0A)","0.42A","5j5xA-4xufA:14.9","5j5xA-4xufA:24.25"],["5J5X_B_AZ1B2_1","4yff","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE TNNI3K","PF07714(Pkinase_Tyr)",5,"GLY A 470;GLY A 472;VAL A 477;LYS A 490;ASP A 606","4CV A 801 ( 3.9A);None;None;4CV A 801 (-3.9A);4CV A 801 (-3.5A)","0.48A","5j5xA-4yffA:15.1","5j5xA-4yffA:24.66"],["5J5X_B_AZ1B2_1","4ylj","Homo sapiens","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A","PF00069(Pkinase)",5,"GLY A 166;GLY A 168;SER A 169;VAL A 173;LYS A 188","4E1 A 505 (-3.5A);4E1 A 505 ( 4.9A);None;4E1 A 505 (-4.5A);4E1 A 505 (-2.7A)","0.55A","5j5xA-4yljA:25.2","5j5xA-4yljA:25.07"],["5J5X_B_AZ1B2_1","5es1","Homo sapiens","MAP\/MICROTUBULE AFFINITY-REGULATING KINASE 4","PF00069(Pkinase);PF00627(UBA)",5,"GLY A  63;GLY A  65;VAL A  70;LYS A  85;ASP A 196","5RC A4000 ( 4.3A);5RC A4000 ( 3.9A);5RC A4000 (-4.6A);5RC A4000 (-2.8A);5RC A4000 (-3.6A)","0.57A","5j5xA-5es1A:28.4","5j5xA-5es1A:32.33"],["5J5X_B_AZ1B2_1","5fd2","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE B-RAF","PF07714(Pkinase_Tyr)",5,"GLY A 464;GLY A 466;VAL A 471;LYS A 483;ASP A 594","None;None;5XJ A 801 (-4.6A);5XJ A 801 (-3.8A);None","0.52A","5j5xA-5fd2A:16.0","5j5xA-5fd2A:25.68"],["5J5X_B_AZ1B2_1","5fm2","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET","PF07714(Pkinase_Tyr)",4,"GLY A 731;GLY A 733;VAL A 738;LYS A 758","PP1 A2012 ( 3.9A);None;PP1 A2012 (-4.4A);PP1 A2012 (-4.1A)","0.44A","5j5xA-5fm2A:24.4","5j5xA-5fm2A:26.24"],["5J5X_B_AZ1B2_1","5idn","Homo sapiens","CYCLIN-DEPENDENT KINASE 8","PF00069(Pkinase)",4,"GLY A  28;GLY A  30;VAL A  35;LYS A  52","6A7 A 401 (-3.6A);None;6A7 A 401 ( 4.5A);6A7 A 401 ( 2.9A)","0.40A","5j5xA-5idnA:23.7","5j5xA-5idnA:25.55"],["5J5X_B_AZ1B2_1","5ig1","Salpingoeca rosetta","CAMK\/CAMK2 PROTEIN KINASE","PF00069(Pkinase)",4,"GLY A  25;GLY A  27;VAL A  32;LYS A  47","None","0.41A","5j5xA-5ig1A:28.6","5j5xA-5ig1A:28.88"],["5J5X_B_AZ1B2_1","5j5t","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3","PF00069(Pkinase)",4,"GLY A  23;VAL A  30;LYS A  45;ASP A 154","None;6G2 A 901 ( 4.9A);6G2 A 901 ( 3.9A);6G2 A 901 (-3.4A)","0.39A","5j5xA-5j5tA:23.6","5j5xA-5j5tA:25.48"],["5J5X_B_AZ1B2_1","5j9z","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",4,"GLY A 719;GLY A 721;VAL A 726;LYS A 745","6HJ A1101 ( 4.2A);None;6HJ A1101 ( 4.7A);6HJ A1101 (-4.2A)","0.41A","5j5xA-5j9zA:22.6","5j5xA-5j9zA:24.46"],["5J5X_B_AZ1B2_1","5lpz","Arabidopsis thaliana","PROTEIN BRASSINOSTEROID INSENSITIVE 1","PF00069(Pkinase)",5,"GLY A 890;GLY A 892;VAL A 897;LYS A 911;ASP A1027","ADP A1200 ( 4.0A);None;ADP A1200 (-4.4A);ADP A1200 ( 4.3A);ADP A1200 (-3.4A)","0.82A","5j5xA-5lpzA:22.3","5j5xA-5lpzA:27.95"],["5J5X_B_AZ1B2_1","5lxd","Homo sapiens","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 2","PF00069(Pkinase)",5,"GLY A 156;GLY A 158;SER A 159;VAL A 163;LYS A 178","7A7 A 501 (-3.2A);None;None;7A7 A 501 (-4.4A);7A7 A 501 (-3.5A)","0.63A","5j5xA-5lxdA:25.1","5j5xA-5lxdA:26.59"],["5J5X_B_AZ1B2_1","5lxd","Homo sapiens","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 2","PF00069(Pkinase)",5,"GLY A 156;GLY A 158;VAL A 163;LYS A 178;ASP A 295","7A7 A 501 (-3.2A);None;7A7 A 501 (-4.4A);7A7 A 501 (-3.5A);7A7 A 501 (-3.2A)","0.51A","5j5xA-5lxdA:25.1","5j5xA-5lxdA:26.59"],["5J5X_B_AZ1B2_1","5tur","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PIM-1","no annotation",5,"GLY A  45;GLY A  47;VAL A  52;LYS A  67;ASP A 186","None;None;7LK A 401 (-4.9A);None;None","0.85A","5j5xA-5turA:28.9","5j5xA-5turA:23.37"],["5J5X_B_AZ1B2_1","5u7q","Homo sapiens","RHO-ASSOCIATED PROTEIN KINASE 2","PF00069(Pkinase)",5,"GLY A  99;GLY A 101;VAL A 106;LYS A 121;ASP A 232","None","0.85A","5j5xA-5u7qA:36.5","5j5xA-5u7qA:34.09"],["5J5X_B_AZ1B2_1","5u94","Mycobacterium tuberculosis","SERINE\/THREONINE-PROTEIN KINASE PKNB","no annotation",5,"GLY A  18;GLY A  20;VAL A  25;LYS A  40;ASP A 156","G93 A 301 ( 3.2A);None;G93 A 301 (-3.4A);G93 A 301 (-3.0A);G93 A 301 ( 3.2A)","0.61A","5j5xA-5u94A:27.6","5j5xA-5u94A:13.94"],["5J5X_B_AZ1B2_1","5vcx","Homo sapiens","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","PF00069(Pkinase)",5,"GLY A 117;GLY A 119;SER A 120;VAL A 124;LYS A 139","H8H A 401 ( 3.7A);None;None;H8H A 401 (-4.7A);H8H A 401 (-4.9A)","0.66A","5j5xA-5vcxA:24.1","5j5xA-5vcxA:26.57"],["5J5X_B_AZ1B2_1","5xv7","Homo sapiens","SERINE-ARGININE (SR) PROTEIN KINASE 1","no annotation",4,"GLY A  87;GLY A  89;VAL A  94;LYS A 109","EMH A 705 ( 3.9A);None;EMH A 705 ( 4.4A);EMH A 705 ( 4.8A)","0.49A","5j5xA-5xv7A:23.8","5j5xA-5xv7A:10.32"],["5J5X_B_AZ1B2_1","5xzw","Saccharomyces cerevisiae","SERINE\/THREONINE-PROTEIN KINASE RAD53","no annotation",4,"GLY A 205;GLY A 207;VAL A 212;LYS A 227","None","0.47A","5j5xA-5xzwA:22.4","5j5xA-5xzwA:24.31"],["5J5X_B_AZ1B2_1","5y86","Homo sapiens","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 3","no annotation",5,"GLY A 216;GLY A 218;VAL A 223;LYS A 238;ASP A 355","None;PO4 A 602 (-3.5A);HRM A 601 ( 4.9A);HRM A 601 (-3.3A);HRM A 601 (-4.7A)","0.72A","5j5xA-5y86A:24.8","5j5xA-5y86A:12.46"],["5J5X_B_AZ1B2_1","6b4w","Homo sapiens","DUAL SPECIFICITY PROTEIN KINASE TTK","no annotation",4,"GLY A 532;GLY A 534;VAL A 539;LYS A 553","CQ7 A 801 ( 4.0A);None;CQ7 A 801 ( 4.8A);CQ7 A 801 (-3.2A)","0.43A","5j5xA-6b4wA:23.4","5j5xA-6b4wA:24.94"],["5J5X_B_AZ1B2_1","6bql","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2","no annotation",5,"GLY A 172;GLY A 174;SER A 175;VAL A 179;LYS A 194","BI9 A 501 (-3.6A);None;ACT A 504 (-3.3A);BI9 A 501 ( 4.8A);NH4 A 506 ( 4.4A)","0.46A","5j5xA-6bqlA:29.4","5j5xA-6bqlA:13.46"],["5J5X_B_AZ1B2_1","6c0t","Homo sapiens","CGMP-DEPENDENT PROTEIN KINASE 1","no annotation",4,"GLY A 367;GLY A 369;VAL A 374;LYS A 390","EE4 A 701 (-3.9A);EE4 A 701 (-3.4A);EE4 A 701 (-4.4A);DMS A 702 (-3.5A)","0.29A","5j5xA-6c0tA:41.6","5j5xA-6c0tA:18.94"],["5J5X_B_AZ1B2_1","6c9d","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE MARK1,SERINE\/THREONINE-PROTEIN KINASE MARK1","no annotation",5,"GLY A  67;GLY A  69;PHE A  71;VAL A  74;LYS A  89","None","0.69A","5j5xA-6c9dA:30.1","5j5xA-6c9dA:13.38"],["5J5X_B_AZ1B2_1","6c9d","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE MARK1,SERINE\/THREONINE-PROTEIN KINASE MARK1","no annotation",5,"GLY A  67;GLY A  69;VAL A  74;LYS A  89;ASP A 200","None","0.51A","5j5xA-6c9dA:30.1","5j5xA-6c9dA:13.38"],["5J5X_B_AZ1B2_1","6ccf","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 1","no annotation",5,"GLY A 135;GLY A 137;VAL A 142;LYS A 157;ASP A 293","H1N A 501 ( 3.8A);None;H1N A 501 (-4.4A);H1N A 501 (-2.8A);H1N A 501 (-3.5A)","0.78A","5j5xA-6ccfA:28.4","5j5xA-6ccfA:13.76"],["5J5X_B_AZ1B2_1","6fyl","Homo sapiens","DUAL SPECIFICITY PROTEIN KINASE CLK2","no annotation",4,"GLY A 170;GLY A 172;VAL A 177;LYS A 193","3NG A 501 (-3.5A);3NG A 501 ( 4.5A);3NG A 501 ( 4.4A);3NG A 501 (-3.0A)","0.34A","5j5xA-6fylA:25.1","5j5xA-6fylA:undetectable"],["5J5X_B_AZ1B2_1","6fyo","Homo sapiens","DUAL SPECIFICITY PROTEIN KINASE CLK1","no annotation",5,"GLY A 168;GLY A 170;VAL A 175;LYS A 191;ASP A 325","None;None;None;EAQ A 501 (-3.2A);EAQ A 501 (-4.6A)","0.70A","5j5xA-6fyoA:25.7","5j5xA-6fyoA:undetectable"],["5J5X_B_AZ1B2_1","6fyv","Homo sapiens","DUAL SPECIFICITY PROTEIN KINASE CLK4","no annotation",5,"GLY A 168;GLY A 170;VAL A 175;LYS A 191;ASP A 325","3NG A 501 (-3.5A);3NG A 501 ( 4.9A);3NG A 501 ( 4.3A);3NG A 501 (-2.7A);3NG A 501 (-4.3A)","0.68A","5j5xA-6fyvA:25.6","5j5xA-6fyvA:undetectable"]]